Cymbalta news from FiercePharma
NewsProfits rise at Novartis, Merck, Lilly
Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from Read more...
Lilly predicts double-digit earnings growth
Here's one bright spot today: Eli Lilly predicts a big year in 2008, with 14 percent growth in net profits and seven billion-dollar-plus products. Higher sales of drugs for depression (Read more...
Lilly cited for"misleading" Cymbalta ads
While Eli Lilly's CEO was out lobbying for drug safety, the FDA was posting a letter on its website warning the drug maker to stop making "false and misleading" claims about its antidepressant Read more...
Lilly pursues new Cymbalta approval
What do you do with a booming antidepressant? Broaden its scope, of course. Eli Lilly has filed for FDA approval to sell Cymbalta as a fibromyalgia remedy. It's already marketed for use against Read more...
| Press ReleasesPRESS RELEASE: Warning Letter on Cymbalta Michele Sharp, Pharm.D. Manager, U.S. Regulatory Affairs Eli Lilly and Company Lilly Technology Center Indianapolis, IN 46221 Re: NDA # 21-733 CYMBALTA® (duloxetine hydrochloride) Delayed-release Read more... |
Get more Cymbalta coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight